ReviewPharmaceutics2021
Curcumin and Its Modified Formulations on Inflammatory Bowel Disease (IBD): The Story So Far and Future Outlook.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.Frontiers in nutrition · 2025Pooled it
- Dietary Bioactive Compounds: Cellular Sensory Pathways, Microbial Partners, and Clinical Realities.Nutrients · 2026Review
- Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.RSC advances · 2026Review
- Cedrol ameliorates ulcerative colitisWorld journal of gastroenterology · 2026Article
- Curcumin's Therapeutic Potential in Ovarian Cancer: Current Insights and Future Perspectives.Food science & nutrition · 2025Review
- Targeting NLRP3 inflammasome with curcumin: mechanisms and therapeutic promise in chronic inflammation.Inflammopharmacology · 2025Review
- Curcumin Ameliorates DSS-Induced Colitis in Mice Through Modulation of Gut Microbiota and Metabolites.Life (Basel, Switzerland) · 2025Article
- Targeting Interferon-Gamma (IFN-γ)-Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances.Mediators of inflammation · 2025Review
- Research advances in nanomaterials with aromatic functional groups for the treatment of inflammatory bowel disease.Frontiers in bioengineering and biotechnology · 2025Review
- The Dynamic Role of Curcumin in Mitigating Human Illnesses: Recent Advances in Therapeutic Applications.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Formulation, characterization, and evaluation of curcumin-loaded ginger-derived nanovesicles for anti-colitis activity.Journal of pharmaceutical analysis · 2024Article
- Drug Interaction-Informed Approaches to Inflammatory Bowel Disease Management.Pharmaceutics · 2024Review
- Treatment of Inflammatory Bowel Disease by Using Curcumin-Containing Self-Microemulsifying Delivery System: Macroscopic and Microscopic Analysis.Pharmaceutics · 2024Article
- Effect of Curcumin Plus Piperine on Redox Imbalance, Fecal Calprotectin and Cytokine Levels in Inflammatory Bowel Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Advancing Gastrointestinal Health: Curcumin's Efficacy and Nanopreparations.Molecules (Basel, Switzerland) · 2024Review
- The Modulatory Effects of Curcumin on the Gut Microbiota: A Potential Strategy for Disease Treatment and Health Promotion.Microorganisms · 2024Review
- Extracts with Nutritional Potential and Their Influence on the Rheological Properties of Dough and Quality Parameters of Bread.Foods (Basel, Switzerland) · 2024Article
- Use of curcumin and its nanopreparations in the treatment of inflammatory bowel disease.World journal of gastroenterology · 2024Article
- Nanostructure Lipid Carrier of Curcumin Co-Delivered with Linalool and Geraniol Monoterpenes as Acetylcholinesterase Inhibitor ofMolecules (Basel, Switzerland) · 2024Article
- The efficacy of curcumin/Qing Dai combination in children with active ulcerative colitis: a multicenter retrospective cohort study.Frontiers in pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory disorder of the small intestine and colon. IBD includes ulcerative colitis (UC) and Crohn's disease (CD), and it is a major factor for the development of colon cancer, referred to as colitis-associated cancer (CAC). The current treatment of IBD mainly includes the use of synthetic drugs and monoclonal antibodies. However, these drugs have side effects over long-term use, and the high relapse rate restricts their application. In the recent past, many studies had witnessed a surge in applying plant-derived products to manage various diseases, including IBD. Curcumin is a bioactive component derived from a rhizome of turmeric (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.